Raves and risks for erythropoietin.

@article{Maiese2008RavesAR,
  title={Raves and risks for erythropoietin.},
  author={Kenneth Maiese and Zhao Zhong Chong and Yan Chen Shang},
  journal={Cytokine & growth factor reviews},
  year={2008},
  volume={19 2},
  pages={145-55}
}
Global use of erythropoietin (EPO) continues to increase as a proven agent for the treatment of anemia. Yet, EPO is no longer believed to have exclusive biological activity in the hematopoietic system and is now considered applicable for a variety of disorders such as diabetes, Alzheimer's disease, and cardiovascular disease. Treatment with EPO is considered to be robust and can prevent metabolic compromise, neuronal and vascular degeneration, and inflammatory cell activation. On the converse… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 81 references

Similar Papers

Loading similar papers…